Gifu University Hospital

Gifu, Gifu 501-1194

0 studies enrolling now · 10 studies all time

What they study most

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Cancer, Multiple System Atrophy, Spinal Cord Injury, Systemic Lupus Erythematosus (SLE), Ulcerative Colitis

Studies at this site

• A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. — Stopped early
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) — Running, not enrolling
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Completed
• A Study of Lu AF82422 in Participants With Multiple System Atrophy — Running, not enrolling
• Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis — Stopped early
• Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury — Completed
• Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed